Objective: The aim of our study was to evaluate the toxicity and efficacy of induction chemotherapy (ICT) followed by three-dimensional conformal radiotherapy (3D CRT) and concurrent weekly paclitaxel on unresectable non-small cell lung cancer (NSCLC). Methods: Stage Ⅲ NSCLC patients with favorable conditions were treated with 2 to 4 cycles of carboplatin (AUC = 5-6, d1) combined with paclitaxel (175 mg/m2 , d1), then followed by weekly paclitaxel (40 mg/m2 ) and concurrent 3D CRT within 3-4 weeks. The prescription dose was given as high as possible under the condition that V20 ≤ 31% and spinal cord dose ≤ 50 Gy. Results: Thirty-one patients were enrolled. ICT was well tolerated. During the concurrent chemoradiotherapy, the treatment of 3 patients was ended ahead of the schedule because of severe pulmonary and heart toxicities; the treatment of 2 patients was delayed for 7 and 12 days because of fatigue. Myelosuppression was mild (16/31): all were grade 1-2 except 1 was grade 3. Lymphocytopenia was more obvious (29/31, grade 3 in 21). Three patients developed grade 3 radiation-induced esophagitis, and 2 developed grades 3-4 radiation-induced pneumonitis. Two developed grade 3 esophageal stricture. No grades 3-4 pulmonary fibrosis was observed. The overall response rate was 74.1%. The 1-, 2-, 3-year overall survival rates were 74.2%, 41.9%, and 34.6%, respectively, with the median survival time of 18.5 months. The 1-, 2-, 3-year local progression-freely survival rates were 64.5%, 32.3%, and 20.5%, respectively, with the median local progression-freely survival time of 14.3 months. Conclusion: The program of ICT followed by weekly paclitaxel and 3D CRT is accomplished in most of the favorable stage Ⅲ NSCLC patients. The toxicity is tolerable, and the response rate is inspiriting. Objective: The aim of our study was to evaluate the toxicity and efficacy of induction chemotherapy (ICT) followed by three-dimensional conformal radiotherapy (3D CRT) and concurrent weekly paclitaxel on unresectable non-small cell lung cancer (NSCLC). Methods: Stage Ⅲ NSCLC patients with favorable conditions were treated with 2 to 4 cycles of carboplatin (AUC = 5-6, d1) combined with paclitaxel (175 mg / m2, d1), followed by weekly paclitaxel (40 mg / m2) CRT within 3-4 weeks. The prescription dose was given as high as possible under the condition that V20 ≤ 31% and spinal cord dose ≤ 50 Gy. Results: Thirty-one patients were enrolled. ICT was well tolerated. During the concurrent chemoradiotherapy , the treatment of 3 patients was ended ahead of the schedule because of severe pulmonary and heart toxicities; the treatment of 2 patients was delayed for 7 and 12 days because of fatigue. Myelosuppression was mild (16/31): all were grades 1- 2 except 1 was grade 3. Three patients developed grade 3 radiation-induced esophagitis, and 2 developed grades 3-4 radiation-induced pneumonitis. Two developed grade 3 esophageal stricture. No grades 3-4 pulmonary The 1-, 2-, 3-year overall survival rates were 74.2%, 41.9%, and 34.6%, respectively, with the median survival rate of 18.5 months. The 1- , 2-, 3-year local progression-free survival rates were 64.5%, 32.3%, and 20.5%, respectively, with the median local progression-freely survival time of 14.3 months. Conclusion: The program of ICT followed weekly paclitaxel and 3D CRT is accomplished in most of the favorable stage Ⅲ NSCLC patients. The toxicity is tolerable, and the response rate is inspiriting.